Nifty
:
21995.85
Sensex
:
72488.99
-152.05 (-0.69%)
-454.69 (-0.62%)
Nifty
Sensex
:
:
21995.85
72488.99
-152.05 (-0.69%)
-454.69 (-0.62%)

Strides Pharma Science Ltd.

Pharmaceuticals & Drugs - Global

Rating :
61/99

BSE: 532531 | NSE: STAR

NSE BSE
844.85
18-Apr-2024
  • Open
  • High
  • Low
  • Previous Close
  •  843.30
  •  857.00
  •  837.00
  •  839.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  174567
  •  1481.52
  •  865.00
  •  306.40

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 7,756.80
  • N/A
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 10,166.79
  • 0.18%
  • 3.54

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 27.39%
  • 6.73%
  • 22.64%
  • FII
  • DII
  • Others
  • 19.45%
  • 17.94%
  • 5.85%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.65
  • 3.48
  • 3.61

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.60
  • 5.37
  • -9.27

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -48.42
  • -46.85
  • -60.89

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 8.33
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.13
  • 1.82
  • 1.84

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.82
  • 15.78
  • 18.28

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Net Sales
1,037.67
864.85
19.98%
999.43
897.10
11.41%
929.99
940.07
-1.07%
986.37
866.02
13.90%
Expenses
843.86
748.50
12.74%
846.30
798.97
5.92%
763.40
879.92
-13.24%
830.81
823.85
0.84%
EBITDA
193.81
116.34
66.59%
153.13
98.13
56.05%
166.59
60.15
176.96%
155.56
42.16
268.98%
EBIDTM
18.68%
13.45%
15.32%
10.94%
17.91%
6.40%
15.77%
4.87%
Other Income
8.75
26.20
-66.60%
35.85
23.46
52.81%
8.64
13.55
-36.24%
27.12
86.06
-68.49%
Interest
79.28
58.44
35.66%
78.59
67.64
16.19%
76.42
54.54
40.12%
80.52
49.48
62.73%
Depreciation
51.23
60.22
-14.93%
60.10
61.70
-2.59%
59.59
60.40
-1.34%
60.93
60.68
0.41%
PBT
61.99
65.44
-5.27%
-114.64
6.77
-
33.25
-107.01
-
33.89
-58.88
-
Tax
10.10
4.09
146.94%
-7.44
-38.40
-
9.68
-28.07
-
7.09
-131.48
-
PAT
51.88
61.35
-15.44%
-107.20
45.17
-
23.57
-78.94
-
26.81
72.60
-63.07%
PATM
5.00%
7.09%
-10.73%
5.04%
2.53%
-8.40%
2.72%
8.38%
EPS
5.41
-8.86
-
-14.54
2.53
-
-0.79
-15.13
-
-1.06
3.25
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
3,953.46
3,688.39
3,070.25
3,315.87
2,981.12
3,108.33
3,344.37
3,826.22
2,862.19
1,195.85
1,340.96
Net Sales Growth
10.80%
20.13%
-7.41%
11.23%
-4.09%
-7.06%
-12.59%
33.68%
139.34%
-10.82%
 
Cost Of Goods Sold
1,624.98
1,626.88
1,502.32
1,332.79
1,122.48
1,085.20
1,378.84
1,281.17
1,502.29
560.49
714.67
Gross Profit
2,328.48
2,061.50
1,567.93
1,983.08
1,858.64
2,023.14
1,965.53
2,545.05
1,359.90
635.37
626.30
GP Margin
58.90%
55.89%
51.07%
59.81%
62.35%
65.09%
58.77%
66.52%
47.51%
53.13%
46.71%
Total Expenditure
3,284.37
3,303.09
3,091.76
2,689.06
2,470.90
2,811.65
3,108.66
3,309.30
2,481.62
967.00
1,117.54
Power & Fuel Cost
-
85.82
71.54
64.58
64.49
54.39
51.33
33.87
77.18
16.02
18.56
% Of Sales
-
2.33%
2.33%
1.95%
2.16%
1.75%
1.53%
0.89%
2.70%
1.34%
1.38%
Employee Cost
-
732.02
646.91
550.15
442.56
329.44
434.05
419.16
357.69
172.06
157.18
% Of Sales
-
19.85%
21.07%
16.59%
14.85%
10.60%
12.98%
10.95%
12.50%
14.39%
11.72%
Manufacturing Exp.
-
259.45
255.52
237.94
210.79
150.98
115.97
137.47
119.23
41.37
35.76
% Of Sales
-
7.03%
8.32%
7.18%
7.07%
4.86%
3.47%
3.59%
4.17%
3.46%
2.67%
General & Admin Exp.
-
232.21
223.67
191.73
191.89
150.10
194.38
172.63
198.71
86.25
66.37
% Of Sales
-
6.30%
7.29%
5.78%
6.44%
4.83%
5.81%
4.51%
6.94%
7.21%
4.95%
Selling & Distn. Exp.
-
263.65
331.30
223.22
137.07
111.22
208.85
161.12
129.57
61.37
66.67
% Of Sales
-
7.15%
10.79%
6.73%
4.60%
3.58%
6.24%
4.21%
4.53%
5.13%
4.97%
Miscellaneous Exp.
-
103.06
60.51
88.65
301.61
930.33
725.25
1,103.88
96.95
29.44
66.67
% Of Sales
-
2.79%
1.97%
2.67%
10.12%
29.93%
21.69%
28.85%
3.39%
2.46%
4.35%
EBITDA
669.09
385.30
-21.51
626.81
510.22
296.68
235.71
516.92
380.57
228.85
223.42
EBITDA Margin
16.92%
10.45%
-0.70%
18.90%
17.12%
9.54%
7.05%
13.51%
13.30%
19.14%
16.66%
Other Income
80.36
135.22
133.40
59.44
66.70
322.90
920.64
398.08
102.37
38.57
60.23
Interest
314.81
261.14
176.74
150.06
155.72
79.29
196.24
183.10
168.17
47.44
108.88
Depreciation
231.85
243.25
233.01
206.29
187.79
171.85
193.93
198.69
131.25
64.03
56.48
PBT
14.49
16.11
-297.88
329.90
233.42
368.44
766.17
533.20
183.50
155.95
118.30
Tax
19.43
-55.30
-178.26
31.65
17.91
14.49
21.41
51.19
42.45
147.60
40.86
Tax Rate
134.09%
6010.87%
32.91%
8.48%
11.50%
3.71%
2.96%
10.30%
29.87%
99.35%
44.53%
PAT
-4.94
-221.20
-460.21
352.32
143.62
370.31
681.31
399.38
113.21
1.57
50.89
PAT before Minority Interest
15.28
-230.90
-474.25
341.61
137.82
375.57
701.18
445.58
99.68
0.98
50.89
Minority Interest
20.22
9.70
14.04
10.71
5.80
-5.26
-19.87
-46.20
13.53
0.59
0.00
PAT Margin
-0.12%
-6.00%
-14.99%
10.63%
4.82%
11.91%
20.37%
10.44%
3.96%
0.13%
3.80%
PAT Growth
-104.93%
-
-
145.31%
-61.22%
-45.65%
70.59%
252.78%
7,110.83%
-96.91%
 
EPS
-0.54
-24.07
-50.08
38.34
15.63
40.29
74.14
43.46
12.32
0.17
5.54

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
2,212.26
2,359.23
2,776.66
2,527.42
2,648.70
2,463.66
2,748.82
2,657.87
1,144.92
1,006.83
Share Capital
90.30
89.79
89.68
89.56
89.55
89.50
89.42
89.35
59.62
59.57
Total Reserves
2,102.54
2,266.99
2,682.26
2,432.13
2,551.59
2,365.10
2,650.55
2,562.75
1,084.50
947.06
Non-Current Liabilities
1,210.30
965.72
1,264.45
813.65
2,342.88
2,067.29
2,048.67
2,760.03
285.79
306.42
Secured Loans
1,040.81
744.86
873.43
601.79
1,806.45
1,551.09
1,622.87
2,614.88
250.23
274.29
Unsecured Loans
98.98
90.77
9.15
2.12
0.06
0.23
14.84
12.13
17.16
1.24
Long Term Provisions
73.42
64.28
246.50
63.95
52.24
16.55
25.19
14.45
6.02
16.56
Current Liabilities
2,990.20
3,411.68
2,738.35
2,544.86
2,662.24
1,899.30
3,103.87
1,891.98
1,019.94
707.37
Trade Payables
982.34
1,071.52
1,134.20
797.75
888.99
712.07
774.09
775.40
234.41
262.31
Other Current Liabilities
527.89
697.18
421.00
354.49
248.12
129.98
819.08
347.93
502.47
127.27
Short Term Borrowings
1,330.76
1,496.53
1,023.84
1,228.78
1,339.02
944.39
1,393.96
700.48
203.03
224.56
Short Term Provisions
149.20
146.43
159.31
163.84
186.11
112.86
116.73
68.19
80.03
93.23
Total Liabilities
6,373.38
6,760.72
6,816.80
5,953.17
7,806.77
6,584.90
8,034.86
7,360.09
2,469.36
2,096.29
Net Block
2,298.42
2,333.45
2,151.13
2,025.85
3,570.13
2,903.00
2,909.03
2,678.68
701.36
554.53
Gross Block
3,324.82
3,231.69
2,841.28
2,534.38
4,049.05
3,229.03
3,186.12
2,825.43
1,080.55
907.33
Accumulated Depreciation
1,026.40
898.24
690.15
508.53
478.92
326.03
277.09
146.75
379.19
352.80
Non Current Assets
3,130.03
3,398.88
3,999.57
3,581.05
4,758.05
4,101.31
4,243.05
3,845.20
1,039.91
787.65
Capital Work in Progress
150.98
291.08
447.37
412.95
453.03
620.29
780.18
814.88
171.17
99.47
Non Current Investment
438.96
540.34
666.23
503.24
494.34
350.08
315.66
127.19
68.76
41.80
Long Term Loans & Adv.
217.18
210.58
185.80
210.82
223.69
197.22
222.56
201.83
96.72
90.40
Other Non Current Assets
11.91
10.26
549.04
428.19
16.86
30.72
15.62
22.62
1.91
1.45
Current Assets
3,135.25
3,361.83
2,817.23
2,372.11
3,048.72
2,483.59
3,791.82
3,514.89
1,429.44
1,308.63
Current Investments
50.84
0.00
99.41
118.97
284.75
311.48
1,279.54
1,213.76
561.29
401.24
Inventories
1,146.51
1,173.80
1,200.70
782.54
874.16
552.02
732.80
613.14
207.68
175.99
Sundry Debtors
1,299.40
1,207.30
1,110.59
931.69
987.18
882.18
995.91
1,032.97
389.96
364.00
Cash & Bank
315.96
187.35
179.76
237.10
516.65
303.33
329.48
311.59
146.88
231.15
Other Current Assets
322.55
647.90
98.22
83.57
385.98
434.59
454.09
343.44
123.64
136.26
Short Term Loans & Adv.
153.34
145.49
128.54
218.24
249.11
295.75
244.39
97.54
54.46
79.06
Net Current Assets
145.05
-49.84
78.89
-172.75
386.48
584.29
687.95
1,622.91
409.50
601.26
Total Assets
6,265.28
6,760.71
6,816.80
5,953.16
7,806.77
6,584.90
8,034.87
7,360.09
2,469.35
2,096.28

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
44.41
-257.81
481.44
204.79
60.05
187.07
288.14
73.25
83.40
-271.68
PBT
-267.63
-652.51
289.38
48.51
344.37
705.80
497.14
146.44
992.01
2,889.87
Adjustment
682.19
582.27
363.31
527.49
94.59
-274.51
190.92
345.56
-756.73
-2,775.01
Changes in Working Capital
-457.80
-189.90
-328.05
-326.23
-323.14
-190.66
-341.30
-341.71
-95.91
-260.68
Cash after chg. in Working capital
-43.23
-260.14
324.64
249.76
115.82
240.63
346.76
150.29
139.37
-145.81
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
87.64
2.33
156.80
-44.98
-55.76
-53.56
-58.62
-77.04
-55.97
-125.87
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
302.47
-118.73
-520.82
1,306.16
-148.49
582.59
-686.69
-2,224.83
51.87
4,077.09
Net Fixed Assets
-54.00
-61.59
-86.75
-167.06
-48.49
677.20
-236.66
-535.93
-66.57
-119.10
Net Investments
-92.01
62.72
-219.57
-17.15
-383.09
747.64
-143.27
-1,478.58
78.09
248.81
Others
448.48
-119.86
-214.50
1,490.37
283.09
-842.25
-306.76
-210.32
40.35
3,947.38
Cash from Financing Activity
-213.92
421.32
-15.80
-1,709.45
194.27
-1,015.69
338.21
2,943.94
-421.25
-3,318.53
Net Cash Inflow / Outflow
132.96
44.77
-55.18
-198.50
105.83
-246.03
-60.33
792.35
-285.98
486.88
Opening Cash & Equivalents
170.73
125.83
182.23
365.89
256.16
515.08
1,110.74
298.91
586.00
132.02
Closing Cash & Equivalent
303.50
170.73
125.83
182.23
365.89
256.16
515.08
1,110.74
298.42
586.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
242.83
262.48
309.09
281.55
294.94
274.26
306.41
296.83
191.91
168.99
ROA
-3.52%
-6.99%
5.35%
2.00%
5.22%
9.59%
5.79%
2.03%
0.04%
1.48%
ROE
-10.15%
-18.49%
12.91%
5.34%
14.74%
27.00%
16.53%
5.25%
0.09%
3.36%
ROCE
-0.49%
-9.49%
11.17%
6.01%
8.65%
16.07%
10.75%
7.54%
10.92%
7.76%
Fixed Asset Turnover
1.91
1.75
2.04
1.50
1.17
1.04
1.27
1.47
1.21
0.61
Receivable days
73.25
79.41
68.09
70.88
79.95
102.49
96.77
90.73
114.71
114.80
Inventory Days
67.80
81.35
66.13
61.20
61.00
70.11
64.20
52.34
58.37
83.78
Payable days
230.40
267.95
264.54
138.58
146.59
116.23
117.33
75.51
76.81
112.69
Cash Conversion Cycle
-89.35
-107.20
-130.32
-6.50
-5.64
56.37
43.64
67.55
96.27
85.89
Total Debt/Equity
1.27
1.18
0.76
0.78
1.22
1.03
1.35
1.34
0.78
0.54
Interest Cover
-0.10
-2.69
3.49
2.00
5.92
4.68
3.71
1.85
4.13
1.84

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013

News Update:


  • Strides Pharma Science’s arm gets USFDA’s approval for Fluoxetine Tabs
    9th Apr 2024, 09:27 AM

    The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug Prozac Tablets of Eli Lilly

    Read More
  • USFDA completes cGMP inspection at Chennai formulations facility of Strides Pharma Science’s arm
    6th Apr 2024, 15:02 PM

    The inspection closed with two observations

    Read More
  • Strides Pharma Science’s arm receives USFDA’s approval for Gabapentin Tablets
    5th Mar 2024, 15:41 PM

    The Gabapentin tablets will be manufactured at the company’s facility in Puducherry

    Read More
  • Strides Pharma Scien - Quarterly Results
    30th Jan 2024, 13:16 PM

    Read More
  • Strides Pharma Science’s arm receives USFDA’s approval for Pregabalin Capsules
    27th Jan 2024, 16:16 PM

    The product is bioequivalent and therapeutically equivalent to the RLD, Lyrica capsules of Upjohn US

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.